ACADIA Pharmaceuticals Inc. (ACAD)

39.95
NASDAQ : Health Technology
Prev Close 39.98
Day Low/High 39.38 / 40.34
52 Wk Low/High 14.01 / 44.85
Avg Volume 2.25M
Exchange NASDAQ
Shares Outstanding 150.74M
Market Cap 6.03B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation Of The Phase 3 HARMONY Study Of Pimavanserin In Dementia-Related Psychosis At The Clinical Trials On Alzheimer's Disease (CTAD) 2019 Meeting

ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation Of The Phase 3 HARMONY Study Of Pimavanserin In Dementia-Related Psychosis At The Clinical Trials On Alzheimer's Disease (CTAD) 2019 Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12 th...

ACADIA Pharmaceuticals To Present At The 2019 Cantor Global Healthcare Conference On October 2, 2019

ACADIA Pharmaceuticals To Present At The 2019 Cantor Global Healthcare Conference On October 2, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Announces That The Journal Of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results For Pimavanserin As Adjunctive Treatment For Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Announces That The Journal Of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results For Pimavanserin As Adjunctive Treatment For Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), announced today that positive results from the Phase 2 CLARITY study evaluating pimavanserin as adjunctive treatment in patients with major depressive disorder (MDD) have been published online by The Journal of...

Acadia Pharma Jumps on Positive Data From Depression Treatment Candidate

Acadia Pharma Jumps on Positive Data From Depression Treatment Candidate

Acadia announces positive results from an eight-week, open label, phase 2 study for a treatment candidate for Parkinson's patients with depressive symptoms.

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its...

ACADIA Pharmaceuticals To Present New Clinical Data And Outcomes Research At Upcoming Scientific Meetings

ACADIA Pharmaceuticals To Present New Clinical Data And Outcomes Research At Upcoming Scientific Meetings

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will present several scientific posters at the upcoming International Congress of Parkinson's Disease and Movement Disorders ® on September 22-26, 2019 in Nice, France and at the annual Psych...

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to...

Ford, Domo, Acadia Pharmaceuticals: 'Mad Money' Lightning Round

Ford, Domo, Acadia Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer takes a look at Ford, Domo, Acadia Pharmaceuticals, Forescout Technologies, Covetrus, Arrow Electronics and more.

Positive Developments for These 3 Biotech Stocks

Positive Developments for These 3 Biotech Stocks

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.

ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint,...

ACADIA Pharmaceuticals To Present At The Morgan Stanley 17th Annual Global Healthcare Conference On September 11, 2019

ACADIA Pharmaceuticals To Present At The Morgan Stanley 17th Annual Global Healthcare Conference On September 11, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for...

Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.

ACADIA Pharmaceuticals Announces Top-line Results From Phase 3 ENHANCE Trial Of Pimavanserin As Adjunctive Treatment For Patients With Schizophrenia

ACADIA Pharmaceuticals Announces Top-line Results From Phase 3 ENHANCE Trial Of Pimavanserin As Adjunctive Treatment For Patients With Schizophrenia

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current...

Notable Thursday Option Activity: ACAD, QTWO, LL

Notable Thursday Option Activity: ACAD, QTWO, LL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc , where a total volume of 13,410 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 142.1% of ACAD's average daily trading volume over the past month, of 943,495 shares.

ACADIA Pharmaceuticals To Announce Second Quarter 2019 Financial Results On July 31, 2019

ACADIA Pharmaceuticals To Announce Second Quarter 2019 Financial Results On July 31, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

2 Attractive Biotechs With Key Study Outcomes on the Horizon

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

New National Event Series "Parkinson's IQ You" Launches To Educate And Empower Parkinson's Disease Patients And Care Partners

New National Event Series "Parkinson's IQ You" Launches To Educate And Empower Parkinson's Disease Patients And Care Partners

- "Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources

ACADIA Pharmaceuticals To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

ACADIA Pharmaceuticals To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present Phase 2 CLARITY Results For Pimavanserin As An Adjunctive Treatment In Major Depressive Disorder At The 2019 American Psychiatric Association Annual Meeting

ACADIA Pharmaceuticals To Present Phase 2 CLARITY Results For Pimavanserin As An Adjunctive Treatment In Major Depressive Disorder At The 2019 American Psychiatric Association Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2019

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for...

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program With Pimavanserin As Adjunctive Treatment For Major Depressive Disorder

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program With Pimavanserin As Adjunctive Treatment For Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of...

ACADIA Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

ACADIA Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Supports Parkinson's Disease Awareness Month And World Parkinson's Day With Local Educational Initiatives And Community Events Across The Country

ACADIA Pharmaceuticals Supports Parkinson's Disease Awareness Month And World Parkinson's Day With Local Educational Initiatives And Community Events Across The Country

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several...

ACADIA Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 9, 2019

ACADIA Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 9, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

TheStreet Quant Rating: D (Sell)